AstraZeneca has announced
a US$2.7 billion deal to acquire
US cardiovascular and metabolic
disease specialist ZS Pharma.
Expected to settle before the end
of the year, the acquisition will see
AZ acquire ZS-9 (sodium zirconium
cyclosilicate), a “potential best-inclass
treatment for hyperkalaemia,”
the firm said.The above article was sent to subscribers in Pharmacy Daily's issue from 10 Nov 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Nov 15
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.